The Motley Fool

The US economy could slow down. Here’s what I’d do

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background
Image source: Getty Images

So far, the US economy seems to be doing quite well. But I think we may have to brace ourselves for slower than anticipated growth in the near future. Investment bank Goldman Sachs, has just cut its US economy forecast to 6% this year from 6.4% earlier. This is based on a larger than expected impact of the Delta variant. 

Now, even 6% growth is not bad. Also, this number is only for the US. So why am I taking note of this? The reason is that if there is a rising incidence of the pandemic’s sub-trend in other parts of the world too, forecasts could be slashed elsewhere. So far the forecast reduction is not drastic, but then who is to say what will happen in the future? Also, given the size of the US economy, it impacts the rest of the world to such a high degree. So if it slows down, it would be bad news for pretty much everyone.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story. In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

What I’d buy now

In this case, I would focus on defensive stocks that can be safe havens if stock markets are rocked by softer than expected US growth. That means stocks that have resilient demand, irrespective of the state of the economy. 

One example of a FTSE 100 defensive stock I like is healthcare biggie AstraZeneca (LSE: AZN), which I also hold in my portfolio already. It needs no introduction, of course, not after its Covid vaccine was developed. But besides manufacturing the vaccine, the Anglo-Swedish pharmaceuticals multinational boasts other notable positives too. 

The case for AstraZeneca

It specialises in cancer treatments, which have been growing their markets. It is a financially healthy company that expects to continue performing well in the foreseeable future. I see this as a key reason for its share price usually bouncing back even after setbacks. 

It suffered one in the second half of last year as stock markets turned bullish. Investors probably got nervous after it announced the acquisition of US-based Alexion, tplus here were doubts about its Covid-19 vaccine and then there was a disagreement with the European Union on the distribution of said vaccines. The effect on its share price was visible until early this year, though it has made a fair bit of a recovery since. It even pays a dividend. 

The upshot

Its price-to-earnings (P/E) ratio is pretty high at 42 times, but in the time that I have covered the stock, I have never seen it being particularly low. I think investors just expect to pay a premium for a company whose earnings are strong and demand for whose products is resilient. Since its earnings forecasts look good, the stock could continue to rise even now, I believe. And this will be even more so if bearishness returns to the markets. It is a buy for me. 

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Manika Premsingh owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.